

SERVICE	LIMITATIONS
12. <u>Prescribed Drugs, Dentures, and Prosthetic Devices, and Eyeglasses</u>	
12.a. Prescribed Drugs (continued)	<p data-bbox="557 323 805 350"><u>Limitations on Payment</u></p> <ol style="list-style-type: none"> <li data-bbox="557 407 1495 459">3. Drugs not included on the Preferred Drug List, and designated as non-preferred.</li> <li data-bbox="647 464 932 491">4. Botulinum Toxins</li> <li data-bbox="647 495 850 522">5. <i>Reserved</i></li> <li data-bbox="647 527 834 554">6. Synagis</li> <li data-bbox="647 558 810 585">7. Xolair</li> <li data-bbox="647 590 826 617">8. Tysabri</li> <li data-bbox="557 621 1495 674">9. Early Refills – a request for a refill when more than 15 percent of an earlier-dispensed medication would remain when taken in compliance with the directions and quantity prescribed.</li> <li data-bbox="647 678 850 705">10. <i>Reserved</i></li> <li data-bbox="557 709 1495 762">11. Legend and non-legend cough and cold medications when prescribed for children under 6 (six) years of age.</li> <li data-bbox="647 766 850 793">12. <i>Reserved</i></li> <li data-bbox="647 798 850 825">13. <i>Reserved</i></li> <li data-bbox="557 829 1495 882">14. Benzodiazepines when prescribed for children under age 21 or that represents duplicate therapy.</li> <li data-bbox="647 886 850 913">15. <i>Reserved</i></li> <li data-bbox="647 917 850 945">16. Nuedexta</li> <li data-bbox="647 949 834 976">17. Makena</li> <li data-bbox="647 980 818 1008">18. Xyrem</li> </ol> <p data-bbox="557 1014 927 1041">(f) Drug Rebate Agreements</p> <ol style="list-style-type: none"> <li data-bbox="557 1068 1520 1230">1. The Commonwealth is in compliance with section 1927 of the Social Security Act. The state will cover drugs of federal rebate participating manufacturers. The state is in compliance with reporting requirements for utilization and restrictions to coverage. Pharmaceutical manufacturers can audit utilization data. The unit rebate amount is confidential and cannot be disclosed for purposes other than rebate invoicing and verification.</li> <li data-bbox="557 1262 1520 1341">2. The Commonwealth will be negotiating supplemental rebates in addition to the federal rebates provided for in Title XIX. Rebate agreements between the state and a pharmaceutical manufacturer will be separate from the federal rebates.</li> <li data-bbox="557 1373 1520 1480">3. A rebate agreement between the state and a drug manufacturer for drugs provided to Medicaid recipients, submitted to CMS on October 1, 2005, and entitled "State of Pennsylvania Department of Public Welfare Supplemental Rebate Agreement" has been authorized by CMS.</li> <li data-bbox="557 1512 1520 1728">4. The Commonwealth will continue state-specific supplemental rebates and will also participate in a multi-state pooling program that will negotiate supplemental rebates in addition to federal rebates provided for in Title XIX. This multi-state pooling program is know as The Optimal PDL Solution (TOP\$<sup>sm</sup>). TOP\$<sup>sm</sup> rebate agreements will be separate from the federal rebates. TOP\$<sup>sm</sup> supplemental rebates received by the Commonwealth in excess of those required under the federal drug rebate agreement will be shared with the federal government on the same percentage basis as applied under the federal rebate agreement.</li> <li data-bbox="557 1759 1455 1862">5. CMS has authorized the state of Pennsylvania to enter into "The Optimal PDL Solution (TOP\$<sup>sm</sup>)." The TOP\$<sup>sm</sup> supplemental rebate agreement was authorized by CMS on 3/13/2007 and is effective January 1, 2007 for the state of Pennsylvania.</li> </ol>

TN# 11-025

Supersedes

TN# 11-023 Approval Date

**MAR 19 2012**

Effective Date December 12, 2011